Omniscient received its third FDA 510(k) clearance for the Quicktome Deep Brain workflow, extending its AI connectomic platform into deep brain stimulation. The software uses patient imaging to localize implanted leads, segment deep brain structures, and map the white matter tracts connecting them to wider brain networks. DBS targeting has traditionally relied heavily on general anatomical atlases, while Quicktome adds patient-specific connectivity data to planning.

Omniscient secured a $27.2M Series D to accelerate the commercialization of its AI-enabled brain-mapping technology. The company builds software that maps functional brain networks from imaging data, positioned as a tool layer for neurosurgical planning and neurological care. The round signals investor appetite for the analytics and infrastructure side of neuroimaging, where value accrues to interpretation rather than acquisition. The funding also coincides with a new CPT code, signalling work on the reimbursement layer.